New effective therapies are greatly needed for metastatic uveal melanoma, which has a very poor prognosis with a median survival of less than 1 y. The melanocortin 1 receptor (MC1R) is expressed in 94% of uveal melanoma metastases, and a MC1R-specific ligand (MC1RL) with high affinity and selectivity for MC1R was previously developed. Methods: The 225Ac-DOTA-MC1RL conjugate was synthesized in high radiochemical yield and purity and was tested in vitro for biostability and for MC1R-specific cytotoxicity in uveal melanoma cells, and the lanthanum-DOTA-MC1RL analog was tested for binding affinity. Non–tumor-bearing BALB/c mice were tested for maximum tolerated dose and biodistribution. Severe combined immunodeficient mice bearing uveal melanoma tumors or engineered MC1R-positive and -negative tumors were studied for biodistribution and efficacy. Radiation dosimetry was calculated using mouse biodistribution data and blood clearance kinetics from Sprague–Dawley rat data. Results: High biostability, MC1R-specific cytotoxicity, and high binding affinity were observed. Limiting toxicities were not observed at even the highest administered activities. Pharmacokinetics and biodistribution studies revealed rapid blood clearance (<15 min), renal and hepatobillary excretion, MC1R-specific tumor uptake, and minimal retention in other normal tissues. Radiation dosimetry calculations determined pharmacokinetics parameters and absorbed α-emission dosages from 225Ac and its daughters. Efficacy studies demonstrated significantly prolonged survival and decreased metastasis burden after a single administration of 225Ac-DOTA-MC1RL in treated mice relative to controls. Conclusion: These results suggest significant potential for the clinical translation of 225Ac-DOTA-MC1RL as a novel therapy for metastatic uveal melanoma.
Melanocortin 1 Receptor–Targeted α-Particle Therapy for Metastatic Uveal Melanoma
Narges K. Tafreshi,Christopher J. Tichacek,D. Pandya,M. Doligalski,M. Budzevich,H. Kil,Nikunj B. Bhatt,N. Kock,J. Messina,Epifanio Ruiz,Nella C. Delva,Adam Weaver,W. Gibbons,D. Boulware,N. Khushalani,G. El-Haddad,P. Triozzi,E. Moros,M. McLaughlin,Thaddeus J. Wadas,David C. Morse
Published 2019 in Journal of Nuclear Medicine
ABSTRACT
PUBLICATION RECORD
- Publication year
2019
- Venue
Journal of Nuclear Medicine
- Publication date
2019-02-07
- Fields of study
Medicine
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-40 of 40 references · Page 1 of 1
CITED BY
Showing 1-45 of 45 citing papers · Page 1 of 1